News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Study Published in Journal of Clinical Microbiology Reports the Sensitivity and Specificity of Great Basin Corporation’s Clostridium difficile Molecular Diagnostic Test


8/13/2012 2:51:39 PM

SALT LAKE CITY--(BUSINESS WIRE)--A study published in the August issue of Journal of Clinical Microbiology showed that Great Basin Corporation’s toxigenic Clostridium difficile (C. diff) molecular diagnostic test has a 97 percent sensitivity and 100 percent specificity rate compared with a competing FDA-approved polymerase chain reaction (PCR) test. In May, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for Great Basin’s C. diff assay.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES